Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | ||
Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
Xyrem | Sodium oxybate | Narcolepsy | Do not list | Complete | ||
Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete |